Brokerages expect Alliqua BioMedical, Inc. (NASDAQ:ALQA) to announce earnings per share of ($0.12) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have made estimates for Alliqua BioMedical’s earnings, with the highest EPS estimate coming in at ($0.08) and the lowest estimate coming in at ($0.16). Alliqua BioMedical reported earnings of ($0.30) per share in the same quarter last year, which would suggest a positive year over year growth rate of 60%. The company is scheduled to issue its next earnings report on Friday, November 3rd.

On average, analysts expect that Alliqua BioMedical will report full-year earnings of ($0.49) per share for the current fiscal year, with EPS estimates ranging from ($0.72) to ($0.21). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.20) per share, with EPS estimates ranging from ($0.30) to ($0.12). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Alliqua BioMedical.

Alliqua BioMedical (NASDAQ:ALQA) last posted its earnings results on Thursday, August 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.05. The business had revenue of $5.52 million for the quarter, compared to analysts’ expectations of $5.01 million. Alliqua BioMedical had a negative net margin of 185.30% and a negative return on equity of 101.86%. The business’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.22) EPS.

A number of equities research analysts have recently weighed in on ALQA shares. HC Wainwright set a $2.00 price target on Alliqua BioMedical and gave the stock a “buy” rating in a research note on Thursday, May 11th. ValuEngine lowered Alliqua BioMedical from a “sell” rating to a “strong sell” rating in a research note on Friday, June 2nd. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $1.31.

Several large investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC increased its stake in Alliqua BioMedical by 120.3% in the first quarter. Perceptive Advisors LLC now owns 4,233,951 shares of the company’s stock worth $2,136,000 after buying an additional 2,312,000 shares during the period. Sabby Management LLC increased its stake in Alliqua BioMedical by 93.7% in the first quarter. Sabby Management LLC now owns 2,131,050 shares of the company’s stock worth $1,076,000 after buying an additional 1,030,652 shares during the period. KCG Holdings Inc. increased its stake in Alliqua BioMedical by 777.7% in the first quarter. KCG Holdings Inc. now owns 525,077 shares of the company’s stock worth $265,000 after buying an additional 465,256 shares during the period. Finally, Renaissance Technologies LLC increased its stake in Alliqua BioMedical by 54.2% in the first quarter. Renaissance Technologies LLC now owns 632,800 shares of the company’s stock worth $319,000 after buying an additional 222,400 shares during the period. 24.02% of the stock is owned by hedge funds and other institutional investors.

Alliqua BioMedical (ALQA) opened at 0.29 on Friday. The firm’s 50-day moving average is $0.36 and its 200 day moving average is $0.45. Alliqua BioMedical has a 1-year low of $0.26 and a 1-year high of $1.13. The company’s market cap is $13.33 million.

WARNING: “Alliqua BioMedical, Inc. (ALQA) Expected to Post Earnings of -$0.12 Per Share” was first posted by Daily Political and is the property of of Daily Political. If you are accessing this news story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this news story can be read at

Alliqua BioMedical Company Profile

Alliqua BioMedical, Inc is a provider of advanced wound care solutions. The Company’s businesses include advanced wound care and contract manufacturing. The Company operates through its subsidiaries, such as AquaMed Technologies, Inc and Choice Therapeutics, Inc The Company is engaged in developing a suite of advanced wound care solutions that will enable surgeons, clinicians and wound care practitioners to address the challenges in chronic and acute wounds.

Get a free copy of the Zacks research report on Alliqua BioMedical (ALQA)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Alliqua BioMedical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alliqua BioMedical Inc. and related companies with's FREE daily email newsletter.